Phaxiam Therapeutics says it has notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares representing its ordinary shares, which should be effective.
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024 finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
PHAXIAM Therapeutics (NASDAQ:PHXM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current […]
Explore Phaxiam Therapeutics Company Regulatory News (RNS) and non regulatory news updates for the latest insights on their financial performance, stock market status, and corporate governance. Stay informed about Phaxiam Therapeutics share price and industry developments. If you're an investor tracking the latest RNS announcements for Phaxiam Therapeutics or just want to find out what has happened to Phaxiam Therapeutics share price as it happens.
Shares of Phaxiam Therapeutics S.A. (PHXM) gained over 23% on Tuesday morning after the company announced that it extended its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target.